Clinical Trials | December 08, 2025
Pfizer’s therapy scores major win in Phase 3 trial for Hemophilia patients with inhibitors
HYMPAVZI’s safety profile was generally favorable
HYMPAVZI’s safety profile was generally favorable
While Merck can appeal, Halozyme said it expects the order to hold
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
The launch of the study was on the occasion of the International Day of Persons with Disabilities
76 of 180 long COVID-associated genes also linked to ME
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Subscribe To Our Newsletter & Stay Updated
